You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAlbendazole
Accession NumberDB00518  (APRD00782)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
Structure
Thumb
Synonyms
(5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester
5-(Propylthio)-2-carbomethoxyaminobenzimidazole
Albendazol
Albendazol
Albendazole
Albendazolum
Albenza
Eskazole
O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate
Proftril
Ricobendazole
Rycobendazole
Valbazen
Zentel
External Identifiers
  • RS-8852
  • SKF 62979
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AlbenzaTablet, film coated200 mg/1OralAmedra Pharmaceuticals LLC1996-06-11Not applicableUs
AlbenzaTablet, film coated200 mg/1OralRx Pak Division Of Mc Kesson Corporation1996-06-11Not applicableUs
AlbenzaTablet, film coated200 mg/1OralDepartment Of State Health Services, Pharmacy Branch1996-06-11Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AbentelAristopharma
ABZIndoco
AcurePharmix
AdazolRoemmers
ALRadicura
BandVensat
BandyMankind
BazoleNeutro Pharma
Ben-AAcme
BenrodInvision
BentilAlliance
BenzolMercury Lab
BenzoleFlamingo Pharmacueticals
BevindazolVincenti
BiwomZydus
BruzolBruluart
BuxolBuffington's
CentalBrisafarma
ChampsCCM
CicloparWeider
CidazoleJuggat
ClearwormInvision
DalbenKrka
DesparIcofarma
EskazoleGlaxoSmithKline
ZentelGlaxoSmithKline
ZolbenSanofi-Aventis
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIF4216019LN
CAS number54965-21-8
WeightAverage: 265.331
Monoisotopic: 265.088497429
Chemical FormulaC12H15N3O2S
InChI KeyHXHWSAZORRCQMX-UHFFFAOYSA-N
InChI
InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
IUPAC Name
methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate
SMILES
CCCSC1=CC2=C(C=C1)N=C(NC(=O)OC)N2
Pharmacology
IndicationFor the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.
Structured Indications
PharmacodynamicsAlbendazole is a broad-spectrum anthelmintic. The principal mode of action for albendazole is by its inhibitory effect on tubulin polymerization which results in the loss of cytoplasmic microtubules.
Mechanism of actionAlbendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules. The loss of the cytoplasmic microtubules leads to impaired uptake of glucose by the larval and adult stages of the susceptible parasites, and depletes their glycogen stores. Degenerative changes in the endoplasmic reticulum, the mitochondria of the germinal layer, and the subsequent release of lysosomes result in decreased production of adenosine triphosphate (ATP), which is the energy required for the survival of the helminth. Due to diminished energy production, the parasite is immobilized and eventually dies.
TargetKindPharmacological actionActionsOrganismUniProt ID
Tubulin beta-2 chainProteinyes
inhibitor
Pig roundwormF1L7U3 details
Tubulin alpha-1A chainProteinno
inhibitor
HumanQ71U36 details
Tubulin beta-4B chainProteinno
inhibitor
HumanP68371 details
Fumarate reductase flavoprotein subunitProteinunknown
inhibitor
Shewanella oneidensis (strain MR-1)P83223 details
Related Articles
AbsorptionPoorly absorbed from the gastrointestinal tract due to its low aqueous solubility. Oral bioavailability appears to be enhanced when coadministered with a fatty meal (estimated fat content 40 g)
Volume of distributionNot Available
Protein binding70% bound to plasma protein
Metabolism

Hepatic. Rapidly converted in the liver to the primary metabolite, albendazole sulfoxide, which is further metabolized to albendazole sulfone and other primary oxidative metabolites that have been identified in human urine.

SubstrateEnzymesProduct
Albendazole
Not Available
albendazole sulfoneDetails
Albendazole
Not Available
albendazole sulfoxideDetails
Route of eliminationAlbendazole is rapidly converted in the liver to the primary metabolite, albendazole sulfoxide, which is further metabolized to albendazole sulfone and other primary oxidative metabolites that have been identified in human urine. Urinary excretion of albendazole sulfoxide is a minor elimination pathway with less than 1% of the dose recovered in the urine. Biliary elimination presumably accounts for a portion of the elimination as evidenced by biliary concentrations of albendazole sulfoxide similar to those achieved in plasma.
Half lifeTerminal elimination half-life ranges from 8 to 12 hours (single dose, 400mg).
ClearanceNot Available
ToxicitySymptoms of overdose include elevated liver enzymes, headaches, hair loss, low levels of white blood cells (neutropenia), fever, and itching.
Affected organisms
  • Helminthic Microorganisms
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Albendazole can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Albendazole.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Albendazole.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Albendazole.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Albendazole.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Albendazole.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Albendazole.Experimental
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Albendazole.Approved, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Albendazole.Approved, Investigational
AmiodaroneThe metabolism of Albendazole can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Albendazole.Approved
AmodiaquineThe serum concentration of Albendazole can be decreased when it is combined with Amodiaquine.Approved
AnvirzelAnvirzel may decrease the cardiotoxic activities of Albendazole.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Albendazole.Approved
AprepitantThe serum concentration of Albendazole can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Albendazole.Approved, Investigational
AtazanavirThe metabolism of Albendazole can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Albendazole.Approved
AtomoxetineThe metabolism of Albendazole can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Albendazole.Approved, Investigational
AzithromycinThe metabolism of Albendazole can be decreased when combined with Azithromycin.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Albendazole.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Albendazole.Approved, Investigational
BexaroteneThe serum concentration of Albendazole can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Albendazole can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Albendazole can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Albendazole can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Albendazole.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Albendazole.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Albendazole.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Albendazole.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Albendazole.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Albendazole.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Albendazole.Approved
CarbamazepineThe serum concentration of the active metabolites of Albendazole can be reduced when Albendazole is used in combination with Carbamazepine resulting in a loss in efficacy.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Albendazole.Approved
CeritinibThe serum concentration of Albendazole can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Albendazole.Withdrawn
ChloroquineThe serum concentration of Albendazole can be decreased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Albendazole.Approved, Vet Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Albendazole.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Albendazole.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Albendazole.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Albendazole.Approved
ClarithromycinThe metabolism of Albendazole can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Albendazole can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Albendazole.Approved, Illicit
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Albendazole.Approved, Investigational
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Albendazole.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Albendazole.Approved, Nutraceutical
ClotrimazoleThe metabolism of Albendazole can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Albendazole.Approved
CobicistatThe metabolism of Albendazole can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Albendazole.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Albendazole.Approved
ConivaptanThe serum concentration of Albendazole can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Albendazole.Approved
CrizotinibThe metabolism of Albendazole can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Albendazole.Approved, Investigational
CyclosporineThe metabolism of Albendazole can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Albendazole can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Albendazole.Approved
DabrafenibThe serum concentration of Albendazole can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Albendazole.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Albendazole.Approved
DarunavirThe metabolism of Albendazole can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Albendazole can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Albendazole.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Albendazole.Approved
DeferasiroxThe serum concentration of Albendazole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Albendazole can be decreased when combined with Delavirdine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Albendazole.Approved
DexamethasoneThe serum concentration of Albendazole can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Albendazole.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Albendazole.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Albendazole.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Albendazole.Approved
DihydroergotamineThe metabolism of Albendazole can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Albendazole.Illicit
DiltiazemThe metabolism of Albendazole can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Albendazole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Albendazole.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Albendazole.Approved, Investigational, Vet Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Albendazole.Approved, Investigational
DoxycyclineThe metabolism of Albendazole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Albendazole can be decreased when combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Albendazole.Approved
EfavirenzThe serum concentration of Albendazole can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Albendazole.Approved, Investigational
EnzalutamideThe serum concentration of Albendazole can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Albendazole.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Albendazole.Approved, Investigational
ErythromycinThe metabolism of Albendazole can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Albendazole can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Albendazole.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Albendazole.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Albendazole.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Albendazole.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Albendazole.Approved
EtravirineThe serum concentration of Albendazole can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Albendazole.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Albendazole.Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Albendazole.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Albendazole.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Albendazole.Approved
FluconazoleThe metabolism of Albendazole can be decreased when combined with Fluconazole.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Albendazole.Approved
FluvoxamineThe metabolism of Albendazole can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Albendazole can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Albendazole can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Albendazole can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Albendazole can be increased when it is combined with Fusidic Acid.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Albendazole.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Albendazole.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Albendazole.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Albendazole.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Albendazole.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Albendazole.Approved, Vet Approved
HydroxychloroquineThe serum concentration of Albendazole can be decreased when it is combined with Hydroxychloroquine.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Albendazole.Approved
IdelalisibThe serum concentration of Albendazole can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Albendazole can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Albendazole.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Albendazole.Approved
IndinavirThe metabolism of Albendazole can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Albendazole.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Albendazole.Approved, Investigational
IsavuconazoniumThe metabolism of Albendazole can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Albendazole can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Albendazole can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Albendazole can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Albendazole.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Albendazole.Approved
KetoconazoleThe metabolism of Albendazole can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Albendazole.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Albendazole.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Albendazole.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Albendazole.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Albendazole.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Albendazole.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Albendazole.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Albendazole.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Albendazole.Approved
LidocaineThe metabolism of Albendazole can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Albendazole.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Albendazole.Approved
LopinavirThe metabolism of Albendazole can be decreased when combined with Lopinavir.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Albendazole.Approved
LovastatinThe metabolism of Albendazole can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Albendazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Albendazole can be increased when combined with Lumacaftor.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Albendazole.Approved, Investigational
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Albendazole.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Albendazole.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Albendazole.Approved, Investigational
MexiletineThe metabolism of Albendazole can be decreased when combined with Mexiletine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Albendazole.Approved, Illicit
MifepristoneThe serum concentration of Albendazole can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Albendazole.Approved
MitotaneThe serum concentration of Albendazole can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Albendazole.Approved, Investigational
ModafinilThe serum concentration of Albendazole can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Albendazole.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Albendazole.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Albendazole.Approved
NafcillinThe serum concentration of Albendazole can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Albendazole.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Albendazole.Approved, Vet Approved
NefazodoneThe metabolism of Albendazole can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Albendazole can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Albendazole can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Albendazole can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Albendazole.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Albendazole.Approved
NilotinibThe metabolism of Albendazole can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Albendazole.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Albendazole.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Albendazole.Approved, Investigational
OlaparibThe metabolism of Albendazole can be decreased when combined with Olaparib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Albendazole.Approved
OsimertinibThe serum concentration of Albendazole can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Albendazole.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Albendazole.Approved, Vet Approved
PalbociclibThe serum concentration of Albendazole can be increased when it is combined with Palbociclib.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Albendazole.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Albendazole.Approved
Peginterferon alfa-2bThe serum concentration of Albendazole can be increased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Albendazole can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of the active metabolites of Albendazole can be reduced when Albendazole is used in combination with Phenobarbital resulting in a loss in efficacy.Approved
PhenytoinThe serum concentration of the active metabolites of Albendazole can be reduced when Albendazole is used in combination with Phenytoin resulting in a loss in efficacy.Approved, Vet Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Albendazole.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Albendazole.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Albendazole.Approved
PosaconazoleThe metabolism of Albendazole can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Albendazole.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Albendazole.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Albendazole.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Albendazole.Approved, Vet Approved
PrimaquineThe serum concentration of Albendazole can be decreased when it is combined with Primaquine.Approved
PrimidoneThe metabolism of Albendazole can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Albendazole.Approved, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Albendazole.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Albendazole.Approved
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Albendazole.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Albendazole.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Albendazole.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Albendazole.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Albendazole.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Albendazole.Approved
RifabutinThe metabolism of Albendazole can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Albendazole can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Albendazole can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Albendazole.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Albendazole.Approved, Investigational
RitonavirThe metabolism of Albendazole can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Albendazole.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Albendazole.Approved, Investigational
RopiniroleThe metabolism of Albendazole can be decreased when combined with Ropinirole.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Albendazole.Approved, Vet Approved
SaquinavirThe metabolism of Albendazole can be decreased when combined with Saquinavir.Approved, Investigational
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Albendazole.Approved
SildenafilThe metabolism of Albendazole can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Albendazole.Approved
SiltuximabThe serum concentration of Albendazole can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Albendazole can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Albendazole.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Albendazole.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Albendazole.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Albendazole.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Albendazole.Experimental
St. John's WortThe serum concentration of Albendazole can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Albendazole can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Albendazole can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Albendazole.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Albendazole.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Albendazole.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Albendazole.Approved
TelaprevirThe metabolism of Albendazole can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Albendazole can be decreased when combined with Telithromycin.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Albendazole.Approved
TenofovirThe metabolism of Albendazole can be decreased when combined with Tenofovir.Approved, Investigational
TeriflunomideThe serum concentration of Albendazole can be decreased when it is combined with Teriflunomide.Approved
TheophyllineThe metabolism of Albendazole can be decreased when combined with Theophylline.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Albendazole.Approved
TiclopidineThe metabolism of Albendazole can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Albendazole.Approved
TocilizumabThe serum concentration of Albendazole can be decreased when it is combined with Tocilizumab.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Albendazole.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Albendazole.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Albendazole.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Albendazole.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Albendazole.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Albendazole.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Albendazole.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Albendazole.Approved
VemurafenibThe serum concentration of Albendazole can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Albendazole.Approved
VenlafaxineThe metabolism of Albendazole can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Albendazole can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Albendazole.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Albendazole.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Albendazole.Approved
VoriconazoleThe metabolism of Albendazole can be decreased when combined with Voriconazole.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Albendazole.Approved
ZiprasidoneThe metabolism of Albendazole can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference

Gyurik, R.J. and Theodorides, VJ.; US. Patent 3,915,986; October 28,1975; assigned to
Smith Kline Corp.

US3915986
General References
  1. Molina AJ, Merino G, Prieto JG, Real R, Mendoza G, Alvarez AI: Absorption and metabolism of albendazole after intestinal ischemia/reperfusion. Eur J Pharm Sci. 2007 May;31(1):16-24. Epub 2007 Feb 6. [PubMed:17350811 ]
  2. Oxberry ME, Reynoldson JA, Thompson RC: The binding and distribution of albendazole and its principal metabolites in Giardia duodenalis. J Vet Pharmacol Ther. 2000 Jun;23(3):113-20. [PubMed:11110097 ]
  3. Ramirez T, Benitez-Bribiesca L, Ostrosky-Wegman P, Herrera LA: In vitro effects of albendazole and its metabolites on the cell proliferation kinetics and micronuclei frequency of stimulated human lymphocytes. Arch Med Res. 2001 Mar-Apr;32(2):119-22. [PubMed:11343808 ]
  4. Haque A, Hollister WS, Willcox A, Canning EU: The antimicrosporidial activity of albendazole. J Invertebr Pathol. 1993 Sep;62(2):171-7. [PubMed:8228321 ]
External Links
ATC CodesP02CA03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9944
Blood Brain Barrier+0.9381
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.6637
P-glycoprotein inhibitor INon-inhibitor0.6928
P-glycoprotein inhibitor IINon-inhibitor0.6089
Renal organic cation transporterNon-inhibitor0.8433
CYP450 2C9 substrateNon-substrate0.7742
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6147
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8347
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8037
Ames testNon AMES toxic0.7894
CarcinogenicityNon-carcinogens0.9334
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.0752 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9707
hERG inhibition (predictor II)Non-inhibitor0.8549
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline llc
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral200 mg/1
Prices
Unit descriptionCostUnit
Albenza 200 mg tablet1.91USD tablet
Albendazole powder0.41USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point208-210Gyurik, R.J. and Theodorides, VJ.; US. Patent 3,915,986; October 28,1975; assigned to Smith Kline Corp.
water solubilityPractically insolubleNot Available
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0228 mg/mLALOGPS
logP3.22ALOGPS
logP3.2ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)9.51ChemAxon
pKa (Strongest Basic)4.27ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.01 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity73.01 m3·mol-1ChemAxon
Polarizability29.3 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassNot Available
Direct ParentBenzimidazoles
Alternative Parents
Substituents
  • Benzimidazole
  • Alkylarylthioether
  • Benzenoid
  • Aminoimidazole
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Azacycle
  • Sulfenyl compound
  • Thioether
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Pig roundworm
Pharmacological action
yes
Actions
inhibitor
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
Not Available
Uniprot ID:
F1L7U3
Molecular Weight:
51336.46 Da
References
  1. Solana HD, Sallovitz JM, Lanusse CE, Rodriguez JA: Enantioselective binding of albendazole sulphoxide to cytosolic proteins from helminth parasites. Methods Find Exp Clin Pharmacol. 2002 Jan-Feb;24(1):7-13. [PubMed:11980387 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Structural molecule activity
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
TUBA1A
Uniprot ID:
Q71U36
Molecular Weight:
50135.25 Da
References
  1. Ramirez T, Benitez-Bribiesca L, Ostrosky-Wegman P, Herrera LA: In vitro effects of albendazole and its metabolites on the cell proliferation kinetics and micronuclei frequency of stimulated human lymphocytes. Arch Med Res. 2001 Mar-Apr;32(2):119-22. [PubMed:11343808 ]
  2. Chu SW, Badar S, Morris DL, Pourgholami MH: Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. Anticancer Res. 2009 Oct;29(10):3791-6. [PubMed:19846910 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Unfolded protein binding
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain.
Gene Name:
TUBB4B
Uniprot ID:
P68371
Molecular Weight:
49830.72 Da
References
  1. Solana HD, Sallovitz JM, Lanusse CE, Rodriguez JA: Enantioselective binding of albendazole sulphoxide to cytosolic proteins from helminth parasites. Methods Find Exp Clin Pharmacol. 2002 Jan-Feb;24(1):7-13. [PubMed:11980387 ]
  2. Chu SW, Badar S, Morris DL, Pourgholami MH: Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole. Anticancer Res. 2009 Oct;29(10):3791-6. [PubMed:19846910 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Shewanella oneidensis (strain MR-1)
Pharmacological action
unknown
Actions
inhibitor
General Function:
Succinate dehydrogenase activity
Specific Function:
Catalyzes fumarate reduction using artificial electron donors such as methyl viologen. The physiological reductant is unknown, but evidence indicates that flavocytochrome c participates in electron transfer from formate to fumarate and possibly also to trimethylamine oxide (TMAO). This enzyme is essentially unidirectional (By similarity).
Gene Name:
Not Available
Uniprot ID:
P83223
Molecular Weight:
62447.475 Da
References
  1. Barrowman MM, Marriner SE, Bogan JA: The fumarate reductase system as a site of anthelmintic attack in Ascaris suum. Biosci Rep. 1984 Oct;4(10):879-83. [PubMed:6518278 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Merino G, Alvarez AI, Prieto JG, Kim RB: The anthelminthic agent albendazole does not interact with p-glycoprotein. Drug Metab Dispos. 2002 Apr;30(4):365-9. [PubMed:11901088 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23